



## MANAGEMENT TEAM

Christopher J. Moreau  
Chief Executive Officer

Dr. Mark Williams, PhD MBA  
Chief Science Officer

Michael Sadhra, CA  
Chief Financial Officer &  
Director

## SENIOR BUSINESS ADVISOR

U.S. Ambassador (Rtd)  
Howard Gutman

## MEDICAL & SCIENTIFIC ADVISORY BOARD

Dr. Arun Sanyal, MD

Dr. Walter Reinisch, MD

Dr. Martin Kolb, MD

## BOARD OF DIRECTORS

Raj Attariwala, MD, PhD

Michael Sadhra, CA

David Levine

## STOCK INFORMATION

(April 30, 2020)

Shares O/S:	110 Million
Warrants & Options:	83 Million
Fully Diluted:	193 Million
90 Day High:	C\$ 0.55
Market Cap:	C\$ 37 Million
Recent Price:	C\$ 0.34

## TRADING SYMBOLS

CSE: AGN

OTCQB: AGNPF

XFRA: AGW

## INVESTOR INQUIRIES

Christopher J. Moreau, CEO  
604.398.4175  
chris@algernonpharmaceuticals.com

## HEAD OFFICE

Algernon Pharmaceuticals Inc.  
Suite 915-700 West Pender St.  
Vancouver, BC, Canada, V6C 1G8

## CORPORATE PRESENTATION

## COMPANY OVERVIEW

Algernon is a drug repurposing company, investigating approved drugs that have an established safety history for new disease applications, moving them efficiently and safely into new human trials, developing new formulations, and seeking new regulatory approvals in billion dollar global disease markets. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life.

Our program specifically investigates compounds that have never been approved in the U.S. or Europe, and we have protected our lead compounds with both method of use and new composition of matter patents for their derivatives and analogues. The Algernon model is highly capital efficient and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

## TARGETED DISEASES

We are focused on the areas of idiopathic pulmonary fibrosis (IPF), chronic cough, non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD), and all of our key compounds for these disease applications were identified using our drug repurposing strategy. The company has developed strong pre-clinical data that supports the advancement of 4 of its leading drug candidates into phase 2 trials in these areas, that either out performed or matched the gold standard of care treatment or one of the leading drugs under development in repeated animal in vivo studies.

Our lead repurposed drug compound NP-120 (Ifenprodil) - an orally delivered small molecule which was originally developed by Sanofi in the 1970s to treat peripheral circulatory disorders and is currently approved for use in South Korea and Japan - is being investigated as a potential therapeutic agent for diseases that cause acute lung injury including IPF, chronic cough and COVID-19.

## COVID-19 GLOBAL INITIATIVES

We are moving aggressively to expand the investigation of our lead repurposed drug compound NP-120 (Ifenprodil) as a new therapeutic treatment for patients who experience respiratory complications as a result of contracting COVID-19. This is based on the strength of Algernon's Ifenprodil animal data for IPF and related chronic cough, independent data on its use in H5N1 infected mice, and additional research showing its potential to reduce the cytokine storm. Algernon has recently been cleared by the U.S. FDA and Health Canada for a multinational Phase 2b/3 human study to evaluate Ifenprodil as a potential therapeutic for COVID-19. The company has applied for ethics approval in Australia to include that country in the study as well and has also received approval for a Phase 2 Ifenprodil human study in South Korea.

The company has additionally received positive feedback from the FDA regarding its plans to reformulate the drug into a new intravenous product best suited for hospital and ICU use. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases.



## RECENT DEVELOPMENTS

### JUNE 4, 2020

Algermon receives U.S. FDA clearance for multinational phase 2b/3 human study to evaluate Ifenprodil as a potential therapeutic for COVID-19

### MAY 25, 2020

Algermon submits Investigational New Drug (IND) Application with U.S. FDA for multinational phase 2b/3 human study to evaluate Ifenprodil for COVID-19

### MAY 15, 2020

Algermon submits for ethics approval in Australia for multinational phase 2b/3 human study of Ifenprodil for COVID-19

### MAY 13, 2020

Algermon announces closing of \$6.8 million private placement offering, including exercise of the over-allotment option

### APRIL 29, 2020

Algermon receives clearance from Health Canada for Ifenprodil COVID-19 phase 2b/3 multinational clinical trial

### APRIL 23, 2020

Algermon receives regulatory and ethics approval for phase 2 Ifenprodil human study in South Korea

### APRIL 22, 2020

Algermon submits application to Health Canada for Ifenprodil COVID-19 phase 2b/3 multinational clinical trial

### APRIL 15, 2020

Algermon receives positive feedback from U.S. FDA for new Ifenprodil intravenous formulation

## ALGERNON CEO INTERVIEWS



Christopher J. Moreau

- **ALGERNON PHARMACEUTICALS RECEIVES U.S. FDA CLEARANCE FOR PHASE 2B/3 IFENPRODIL HUMAN STUDY**
- **ALGERNON PHARMACEUTICALS DISCUSSES MULTINATIONAL PHASE 2B/3 IFENPRODIL COVID-19 HUMAN TRIAL ON BIOPUB WEBCAST HOSTED BY DR. KSS MD PHD**
- **EQUITY INSIGHT INTERVIEW WITH CEO OF ALGERNON PHARMACEUTICALS**

## ALGERNON YTD PRICE HISTORY

JUNE 8, 2020



Click for a real time quote

## KEY DATA

Our confidence in Ifenprodil as a potentially therapeutic compound for diseases that cause acute lung injury including IPF, chronic cough and COVID-19 is based on the data collected from our internal animal studies, as well as data from other independent studies:

### Algermon Ifenprodil Studies

We first investigated Ifenprodil for idiopathic pulmonary fibrosis (IPF), and it outperformed the world's two leading treatments for the disease - Boehringer Ingelheim's Nintedanib and Roche's Pirfenidone - in a pre-clinical *in vivo* animal study, reducing fibrosis by 56% with statistical significance. **IPF Study Media Release**

We additionally investigated Ifenprodil in a recent acute cough animal study where it outperformed Merck's phase 3 drug Gefapixant by 110%. **Acute Cough Study Media Release**

### Independent Ifenprodil Studies

An independent animal study published by the American Society of Microbiology in *mSystems* in the December 2019 issue, found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability with Avian H5N1 infected mice by 40%. Avian H5N1 is the most lethal form of influenza known to man with an over 50% mortality rate. **American Society of Microbiology**

An independent animal study published *in-vivo* also found that Ifenprodil prolonged survival in mice under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function. **NCBIPubMed**